With another earnings season upon us, The Fool's health care team is busy making sure investors know what to expect from their favorite companies this quarter, while also keeping with the Foolish approach of long-term investing.
In this segment, health care bureau chief Brenton Flynn runs through the upcoming earnings from Johnson & Johnson (NYSE: JNJ ) , which will be reporting Tuesday morning.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.